Abstract:HomeCirculation ResearchVol. 97, No. 6The Enigma of β2-Adrenergic Receptor Gi Signaling in the Heart Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBThe Enigma of β2-Adrenergic Receptor Gi Signaling in the HeartThe Good, the Bad, and the Ugly Weizhong Zhu, Xiaokun Zeng, Ming Zheng and Rui-Ping Xiao Weizhong ZhuWeizhong Zhu From the Laboratory of Cardiovascular Science (W.Z., X.Z., R.-P.X.), National Institute of Aging, National Institutes of Health, Baltimore, Md; and The Institute of Molecular Medicine (M.Z., R.-P.X.), Peking University, Beijing, China. Search for more papers by this author , Xiaokun ZengXiaokun Zeng From the Laboratory of Cardiovascular Science (W.Z., X.Z., R.-P.X.), National Institute of Aging, National Institutes of Health, Baltimore, Md; and The Institute of Molecular Medicine (M.Z., R.-P.X.), Peking University, Beijing, China. Search for more papers by this author , Ming ZhengMing Zheng From the Laboratory of Cardiovascular Science (W.Z., X.Z., R.-P.X.), National Institute of Aging, National Institutes of Health, Baltimore, Md; and The Institute of Molecular Medicine (M.Z., R.-P.X.), Peking University, Beijing, China. Search for more papers by this author and Rui-Ping XiaoRui-Ping Xiao From the Laboratory of Cardiovascular Science (W.Z., X.Z., R.-P.X.), National Institute of Aging, National Institutes of Health, Baltimore, Md; and The Institute of Molecular Medicine (M.Z., R.-P.X.), Peking University, Beijing, China. Search for more papers by this author Originally published16 Sep 2005https://doi.org/10.1161/01.RES.0000184615.56822.bdCirculation Research. 2005;97:507–509Four decades ago, it was thought that the cardiac β-adrenergic receptor (AR) was β1AR, the vascular/bronchial counterpart was β2AR, and that β2AR was either nonexistent or nonfunctional in myocardium.1 In the heart, stimulation of β1AR leads to PKA-dependent phosphorylation of a set of Ca2+ regulatory proteins, including sarcolemmal L-type Ca2+ channels, sarcoplasmic reticulum (SR) Ca2+-release channels (ryanodine receptors), SR Ca2+-ATPase (SERCA) and its regulator phospholamban (PLB), and some myofilament proteins, resulting in positive inotropic, lusitropic, and chronotropic effects. However, over the past decade, compelling evidence has shown that the β2AR subtype is expressed in the heart and its signaling and functionalities markedly differ from those evoked by the closely related βAR subtype, the β1AR. Unlike β1AR, β2AR couples dually to Gs and Gi proteins; the β2AR-Gi signaling pathway plays a crucial role in cardioprotection against apoptotic death of myocytes in culture and in vivo (the “good”), while attenuating the β2AR-Gs-mediated inotropic response (the “bad”) (Figure).2 Now, in the current issue of Circulation Research, He et al revealed one “ugly” facet of the β2AR-Gi signaling in a canine heart failure model.3 They demonstrated that in the failing heart, activation of β2AR dampens the ability of β1AR, the primary cardiac subtype, to stimulate ICa,L, thus resulting in an overall dysfunction of βAR inotropic response in the failing heart (Figure).3 Specifically, the effect of βAR stimulation with a nonselective agonist, isoproterenol (ISO), on ICa,L is strikingly diminished in cardiomyocytes from canine failing heart, but can be revived by disruption of Gi function with pertussis toxin (PTX) or β2AR blockade with ICI 118 551.3 These findings highlight that an alteration in the status of the β2AR-Gi coupling can dictate the overall outcome of cardiac βAR signaling under some pathological circumstances. Thus, this enigmatic, multifaceted β2AR-Gi signaling pathway might bear important pathogenic and therapeutic implications. Download figureDownload PowerPointCross Inhibition of β1AR-mediated activation of L-type Ca2+ currents (ICa,L) and positive inotropic effect by enhanced β2AR-Gi signaling in the failing heart. The β2AR-Gi signaling also protects cardiomyocytes against β1AR-mediated apoptosis and maladaptive remodeling via suppressing PKA-independent stimulation of ICa,L and CaMKII (PTX indicates pertussis toxin; PKA, protein kinase A; CaMKII, Ca2+/calmodulin-dependent protein kinase II). In addition, in the normal heart but not the failing heart, heterodimerization of β1AR and β2AR optimizes β-adrenergic modulation of cardiac contractility likely via reducing β2AR-Gi coupling.The “Good”: Cardioprotection Induced by Sustained β2AR StimulationA large body of evidence gleaned from pharmacological and mouse genetic studies has revealed opposing contributions of sustained β1AR and β2AR stimulation in regulating the fate of cardiomyocytes. Whereas sustained β1AR stimulation promotes apoptotic death of cardiomyocytes, sustained stimulation of β2AR protects myocytes against a wide range of apoptotic insults. For instance, agonist-induced β2AR stimulation prevents catecholamine-, hypoxia-, or reactive oxygen species (ROS)-induced apoptotic death in both neonatal and adult rat cardiomyocytes.4–6 Moreover, in adult mice lacking the native β2AR, stimulation of the native β1AR by catecholamine causes overtly exaggerated cardiomyopathy, myocyte apoptosis, and more severe heart failure relative to wild-type control animals.7 In contrast, selective activation of β2AR by fenoterol for 8 weeks exerts a clear antiapoptotic effect and improves cardiac performance in a myocardial infarction–induced rat heart failure model.8 These in vivo studies have provided evidence that β2AR stimulation exerts a cardiac protective effect in response to elevated circulating catecholamine levels or myocardial infarction.The cardiac protective effect of persistent β2AR signaling is largely mediated by β2AR-Gi coupling, which, in turn, activates a cell survival pathway sequentially involving Giβγ, PI3K, and Akt. First, β2AR blockade enhances β1AR-induced apoptosis in cultured adult rat myocytes in a PTX-sensitive manner, suggesting the β2AR protective effect is Gi-dependent.4 Second, β2AR, but not β1AR, activates a Gi-Gβγ-PI3K-Akt cell survival signaling pathway6,9, and inhibition of this pathway abolishes the ability of β2AR to block hypoxia- and ROS-induced myocyte apoptosis.6 Thus, the β2AR-Gi- Gβγ-PI3K-Akt signaling cascade not only counteracts βAR-induced apoptosis and but also protects cardiomyocytes against other apoptotic stimuli.The “ Bad” or “Ugly”: β2AR-coupled Gi Negates β1AR- and β2AR-Mediated Contractile Support in the Failing HeartAlthough beneficial in terms of cardiac protection, the β2AR protective effect comes at the cost of compromised contractile support. Previous studies have demonstrated that the β2AR-Gi functionally restricts the β2AR-Gs–mediated cAMP/PKA signaling to subsarcolemmal microdomain in the vicinity of L-type Ca2+ channels, thus preventing the Gs-PKA mediated phosphorylation of some key target proteins in SR membrane and intracellular contractile myofilaments, blunting the positive inotropic and lusitropic effects.10–13 Activation of PI3K, an important downstream event of the β2AR-Gi signaling, confines and minimizes the concurrent β2AR-Gs–evoked cAMP/PKA signaling.14 In the failing heart, an upregulation of Gi15 and a selective downregulation of β1AR16 are often associated with enhanced β2AR-Gi signaling and reduced myocardial contractile response to both β1AR and β2AR stimulation. Importantly, inhibition of the Gi signaling pathway with PTX restores the diminished βAR inotropic response in a variety of heart failure models, including a spontaneous hypertensive rat heart failure model,17 a myocardial infarction rat heart failure model,18 and myocytes from failing human hearts.19 Furthermore, in failing porcine and mouse hearts or cardiomyocytes, inhibition of βAR-targeted PI3K, the major downstream mediator the Gi signaling, improves the contractile function of the failing myocardium.20,21 Now, He and colleagues demonstrate a cross-inhibition of β1AR-mediated stimulation of ICa,L by the β2AR-Gi signaling.3 Similarly, the β2AR-Gi signaling largely inhibits β1AR-induced positive inotropic effect in adult rat cardiomyocytes moderately overexpressing Na+/Ca2+ exchanger proteins.22 Collectively, these studies suggest that reinforcement of β2AR-Gi signaling is a hallmark of the failing heart and is critically involved in heart failure–associated dysfunction or desensitization of both βAR subtypes.The Cell Logic of Multifaceted β2AR-Gi SignalingAt the first glance, inhibition of the β1AR-mediated stimulation of ICa,L and, consequentially, the contractile response by β2AR-coupled Gi might paint β2AR stimulation as the “bad guy” in the context of heart failure. It is, however, noteworthy that sustained β1AR stimulation induces myocyte apoptosis and positive inotropic effect mainly via PKA-independent stimulation of L-type Ca2+ channels and resultant activation of CaMKII in adult mouse and rat cardiomyocytes (Figure).23,24 Inhibition of ICa,L or CaMKII can effectively protect the cultured cardiomyocytes from β1AR-induced apoptotic death.23 In contrast, overexpression of the L-type channel (α1C) causes severe cardiac hypertrophy and apoptosis.25 Recent in vivo studies have further confirmed that inhibition of CaMKII substantially prevents cardiac maladaptive remodeling from excessive βAR stimulation and myocardial infarction and markedly improves cardiac function (Figure).26 In light of these observations, we envision that the inhibitory effect of the β2AR-Gi signaling on β1AR-mediated activation of ICa,L and resultant CaMKII may represent an intrinsic cardiac protective mechanism, acting as a “friend” rather than a “foe,” to protect the heart against apoptosis and maladaptive remodeling in response to chronic catecholamine stimulation. Thus, the apparent “bad” or “ugly” behavior might be an overreaction of the defense mechanism; appropriately tipping the balance might be able to bring out the “good” nature of β2AR-Gi signaling to benefit the struggling heart.Potential Mechanisms Underlying the Gi-Dependent Crosstalk of βAR SubtypesThe exact mechanism underlying the cross-inhibition of β1AR function by the β2AR-Gi signaling remains elusive. There are several candidate mechanisms, including the β2AR-Gi signaling–mediated direct suppression of adenylyl cyclase activity or activation of PI3K. With respect to the latter, it has been shown that activation of PI3K inhibits ICa,L in normal adult rat cardiomyocytes.27 More importantly, inhibition of membrane-targeted PI3K activity ameliorates cardiac dysfunction and improves survival in multiple heart failure models.20,21Alternatively, we have recently demonstrated that β1AR and β2AR are able to form heterodimers in adult mouse cardiomyocytes and HEK 293 cells.28,29 Specifically, in cardiomyocytes, the heterodimeric receptors exhibit altered ligand binding profiles, enhanced signaling efficiency in regulating myocyte cAMP production and contractility, and suppressed β2AR spontaneous activity in the absence of agonist stimulation, thus optimizing β-adrenergic regulation of cardiac contractility (Figure).28 Interestingly, heterodimerization between β1AR and β2AR inhibits the agonist-promoted internalization of β2AR and its ability to activate the Gi-ERK1/2 MAPK signaling pathway in HEK 293 cells.29 Similarly, whereas either β2AR or β3AR alone couples to both Gs and Gi proteins, the β2AR-β3AR heterodimer is unable to activate Gi signaling.30 Thus, alterations in the status of oligomerization of GPCRs from the same or different families may lead to changes in the selectivity and specificity of G protein coupling of those receptors, thereby altering their signaling and functional features, perhaps also raising important therapeutic considerations.The heart failure–associated decrease in the ratio of β1AR to β2AR,3,16 in conjunction with changes in cardiomyocyte morphology and membrane integrity, might interfere with the heterodimerization of the remaining βARs, thus allowing the β2AR to better couple to Gi proteins. The enhanced Gi signaling inhibits β1AR-mediated increases in ICa,L and contractility, perhaps most importantly, ameliorates β1AR-evoked maladaptive remodeling and loss of cardiomyocytes (Figure). These hypotheses merit future investigation.In summary, it is reasonable to speculate that the selective downregulation of β1AR and the upregulation of β2AR-coupled Gi signaling in the functionally compensated hypertrophied heart may represent salutary cardiac adaptation, which may protect myocytes against apoptosis and maladaptive remodeling and consequently slow the progression of cardiomyopathy and contractile dysfunction. However, exaggerated β2AR-Gi signaling blunts the Gs-mediated stimulation of ICa,L and contractile support, thus contributing to the contractile defect of the failing heart despite of its antiapoptotic effect. Thus, restoration of the Yin and Yang balance of β2AR-coupled Gi and Gs signaling cascades may open a novel therapeutic avenue for the treatment of heart failure.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.This work is supported by National Institutes of Health intramural research grant (to Z.W.Z., X.Z., and R.P.X.), and in part by Chinese National Key Project 973 (G2000056906) and Chinese Young Investigator Award (30225036). The authors thank Dr H. Cheng for critical comments and discussions.FootnotesCorrespondence to Rui-Ping Xiao, MD, PhD, Laboratory of Cardiovascular Science, Gerontology Research Center, NIA, NIH, 5600 Nathan Shock Drive, Baltimore, MD 21224. E-mail [email protected] References 1 Lands AM, Arnold A, Mcauliff JP, Luduena FP, Brown TG. Differentiation of receptor systems activated by sympathomimetic amines. Nature. 1967; 214: 596–598.Google Scholar2 Xiao RP, Zhu W, Zheng M, Bond R, Lakatta EG, Cheng H. Subtype-specific β-adrenergic signaling pathways and their clinical implications. Trends Pharmacol Sci. 2004; 25: 358–365.CrossrefMedlineGoogle Scholar3 He JQ, Balijepalli RC, Haworth RA, Kamp TJ. Crosstalk of β-adrenergic receptor subtypes through Gi blunts β-adrenergic stimulation of L-type Ca2+ channels in canine heart failure. Circ Res. 2005; 97: 566–573.LinkGoogle Scholar4 Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation. 1999; 100: 2210–2212.CrossrefMedlineGoogle Scholar5 Zaugg M, Xu W, Lucchinetti E, Shafiq SA, Jamali NZ, Siddiqui MA. β-adrenergic receptor subtypes differentially affect apoptosis in adult rat ventricular myocytes. Circulation. 2000; 102: 344–350.CrossrefMedlineGoogle Scholar6 Chesley A, Ohtani S, Asai T, Xiao RP, Lunberg MS, Lakatta EG, Crow MT. The β2-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-dependent coupling to phosphatidylinositol 3′-kinase. Circ Res. 2000; 87: 1172–1179.CrossrefMedlineGoogle Scholar7 Patterson AJ, Zhu W, Chow A, Agrawal R, Kosek J, Xiao RP, Kobilka B. Protecting the myocardium: a role for the β2-adrenergic receptor in the heart. Crit Care Med. 2004; 32: 1041–1048.CrossrefMedlineGoogle Scholar8 Ahmet I, Krawczyk M, Heller P, Moon C, Lakatta EG, Talan MI. Beneficial effects of chronic pharmacological manipulation of β-adrenoreceptor subtype signaling in rodent dilated ischemic cardiomyopathy. Circulation. 2004; 110: 1083–1090.LinkGoogle Scholar9 Zhu WZ, Zheng M, Lefkowitz RJ, Koch WJ, Kobilka B, Xiao RP. Dual modulation of cell survival and cell death by β2-adrenergic signaling in adult mouse cardiac myocytes. Proc Natl Acad Sci U S A. 2001; 98: 1607–1612.CrossrefMedlineGoogle Scholar10 Kuschel M, Zhou YY, Cheng H, Zhang SJ, Chen-Izu Y, Lakatta EG, Xiao RP. Gi protein-mediated functional compartmentalization of cardiac β2-adrenergic signaling. J Biol Chem. 1999; 274: 22048–22052.CrossrefMedlineGoogle Scholar11 Chen-Izu Y, Xiao RP, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG. Gi-dependent localization of β2-adrenergic receptor signaling to L-type Ca2+ channels. Biophys J. 2000; 79: 2547–2556.CrossrefMedlineGoogle Scholar12 Xiao RP, Ji X, Lakatta EG. Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol. 1995; 47: 322–329.MedlineGoogle Scholar13 Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA, Eschenhagen T, Lefkowitz RJ, Koch WJ, Lakatta EG. Coupling of β2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res. 1999; 84: 43–52.CrossrefMedlineGoogle Scholar14 Jo SH, Leblais V, Wang PH, Crow MT, Xiao RP. Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent Gs signaling during β2-adrenergic stimulation. Circ Res. 2002; 91: 46–53.LinkGoogle Scholar15 Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A, Hirt S, Doring V, Kalmar P, Hoppner W. Increased messenger RNA level of the inhibitory G protein alpha subunit Gia1 in human end-stage heart failure. Circ Res. 1992; 70: 688–696.CrossrefMedlineGoogle Scholar16 Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S. β1- and β2-adrenergic receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ Res. 1986; 59: 297–309.LinkGoogle Scholar17 Xiao RP, Zhang SJ, Chakir K, Avdonin P, Zhu W, Bond RA, Balke CW, Lakatta EG, Cheng H. Enhanced Gi signaling mediates the diminution of β2-adrenergic contractile response in failing spontaneous hypertensive rat heart. Circulation. 2003; 108: 1633–1639.LinkGoogle Scholar18 Kompa AR, Gu XH, Evans BA, Summers RJ. Desensitization of cardiac β-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat. Evidence for the role of Gi but not Gs or phosphorylating proteins. J Mol Cell Cardiol. 1999; 31: 1185–1201.CrossrefMedlineGoogle Scholar19 Brown LA, Harding SE. The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. Br J Pharmacol. 1992; 106: 115–122.CrossrefMedlineGoogle Scholar20 Perrino C, Naga Prasad SV, Schroder JN, Hata JA, Milano C, Rockman HA. Restoration of β-adrenergic receptor signaling and contractile function in heart failure by disruption of the βARK1/phosphoinositide 3-kinase complex. Circulation. 2005; 111: 2579–2587.LinkGoogle Scholar21 Perrino C, Naga Prasad SV, Patel M, Wolf MJ, Rockman HA. Targeted inhibition of β-adrenergic receptor kinase-1-associated phosphoinositide-3 kinase activity preserves β-adrenergic receptor signaling and prolongs survival in heart failure induced by calsequestrin overexpression. J Am Coll Cardiol. 2005; 45: 1862–1870.CrossrefMedlineGoogle Scholar22 Sato M, Gong H, Terracciano CMN, Ranu H, Harding SE. Loss of β-adrenoceptor response in myocytes overexpressing the Na+/Ca2+-exchanger. J Mol Cell Cardiol. 2004; 36: 43–48.CrossrefMedlineGoogle Scholar23 Zhu WZ, Wang SQ, Chakir K, Kolbilka BK, Cheng H, Xiao RP. Linkage of β1-adrenergic stimulation to apoptotic heart cell death through protein kinase A-independent activation of Ca2+/Calmodulin Kinase II. J Clin Invest. 2003; 111: 617–625.CrossrefMedlineGoogle Scholar24 Wang W, Zhu W, Wang S, Yang D, Crow MT, Xiao RP, Cheng H. Sustained β1-adrenergic stimulation modulates cardiac contractility by Ca2+/calmodulin kinase signaling pathway. Circ Res. 2004; 95: 798–806.LinkGoogle Scholar25 Muth JN, Bodi I, Lewis W, Varadi G, Schwartz A. A Ca2+-dependent transgenic model of cardiac hypertrophy: A role for protein kinase Calpha. Circulation. 2001; 103: 140–147.CrossrefMedlineGoogle Scholar26 Zhang R, Khoo MSC, Wu Y, Yang Y, Grueter CE, Ni G, Price EE Jr, Thiel W, Guatimosim S, Song LS, Madu EC, Shah AN, Vishnivetskaya TA, Atkinson JB, Gurevich VV, Salama G, Lederer WJ, Colbran RJ, Anderson ME. Calmodulin kinase II inhibition protects against structural heart disease. Nature Medicine. 2005; 11: 409–417.CrossrefMedlineGoogle Scholar27 Leblais V, Jo SH, Chakir K, Maltsev V, Zheng M, Crow MT, Wang W, Lakatta EG, Xiao RP. Phosphatidylinositol 3-kinase offsets cAMP-mediated positive inotropic effect via inhibiting Ca2+ influx in cardiomyocytes. Circ Res. 2004; 95: 1183–1190.LinkGoogle Scholar28 Zhu WZ, Chakir K, Zhang S, Yang D, Lavoie C, Bouvier M, Hébert TE, Lakatta EG, Cheng H, Xiao RP. Heterodimerization of β1- and β2-adrenergic receptor subtypes optimizes β-adrenergic modulation of cardiac contractility. Circ Res. 2005; 97: 244–251.LinkGoogle Scholar29 Lavoie C, Mercier JF, Salahpour A, Umapathy D, Breit A, Villeneuve LR, Zhu WZ, Xiao RP, Lakatta EG, Bouvier M, Hebert TE. β1/β2-adrenergic receptor heterodimerization regulates β2-adrenergic receptor internalization and ERK signaling efficacy. J Biol Chem. 2002; 277: 35402–35410.CrossrefMedlineGoogle Scholar30 Breit A, Lagace M, Bouvier M. Hetero-oligomerization between β2- and β3-adrenergic receptors generates a β-adrenergic signaling unit with distinct functional properties. J Biol Chem. 2004; 279: 28756–28765.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Liu Z, Tao B, Fan S, Cui S, Pu Y, Qiu L, Xia H and Xu L (2020) Over-expression of microRNA-145 drives alterations in β-adrenergic signaling and attenuates cardiac remodeling in heart failure post myocardial infarction, Aging, 10.18632/aging.103320, 12:12, (11603-11622), Online publication date: 18-Jun-2020. Lukasheva V, Devost D, Le Gouill C, Namkung Y, Martin R, Longpré J, Amraei M, Shinjo Y, Hogue M, Lagacé M, Breton B, Aoki J, Tanny J, Laporte S, Pineyro G, Inoue A, Bouvier M and Hébert T (2020) Signal profiling of the β1AR reveals coupling to novel signalling pathways and distinct phenotypic responses mediated by β1AR and β2AR, Scientific Reports, 10.1038/s41598-020-65636-3, 10:1 Xu X and Wang D (2020) The progress and controversial of the use of beta blockers in patients with heart failure with a preserved ejection fraction, IJC Heart & Vasculature, 10.1016/j.ijcha.2019.100451, 26, (100451), Online publication date: 1-Feb-2020. Chu S, Peng F, Wang J, Liu L, Meng L, Zhao J, Han X and Ding W (2020) Catestatin in defense of oxidative-stress-induced apoptosis: A novel mechanism by activating the beta2 adrenergic receptor and PKB/Akt pathway in ischemic-reperfused myocardium, Peptides, 10.1016/j.peptides.2019.170200, 123, (170200), Online publication date: 1-Jan-2020. Kayki-Mutlu G, Karaomerlioglu I, Arioglu-Inan E and Altan V (2019) Beta-3 adrenoceptors: A potential therapeutic target for heart disease, European Journal of Pharmacology, 10.1016/j.ejphar.2019.172468, 858, (172468), Online publication date: 1-Sep-2019. Woo A, Ge X, Pan L, Xing G, Mo Y, Xing R, Li X, Zhang Y, Wainer I, Cheng M and Xiao R (2019) Discovery of β-arrestin-biased β2-adrenoceptor agonists from 2-amino-2-phenylethanol derivatives, Acta Pharmacologica Sinica, 10.1038/s41401-018-0200-x, 40:8, (1095-1105), Online publication date: 1-Aug-2019. Cook R, Bussey C, Fomison‐Nurse I, Hughes G, Bahn A, Cragg P and Lamberts R (2019) β 2 ‐Adrenoceptors indirectly support impaired β 1 ‐adrenoceptor responsiveness in the isolated type 2 diabetic rat heart , Experimental Physiology, 10.1113/EP087437, 104:6, (808-818), Online publication date: 1-Jun-2019. Strohman M, Maeda S, Hilger D, Masureel M, Du Y and Kobilka B (2019) Local membrane charge regulates β2 adrenergic receptor coupling to Gi3, Nature Communications, 10.1038/s41467-019-10108-0, 10:1 Huang J, Li C, Song Y, Fan X, You L, Tan L, Xiao L, Li Q, Ruan G, Hu S, Cui W, Li Z, Ni L, Chen C, Woo A, Xiao R and Wang D (2018) ADRB2 polymorphism Arg16Gly modifies the natural outcome of heart failure and dictates therapeutic response to β-blockers in patients with heart failure, Cell Discovery, 10.1038/s41421-018-0058-6, 4:1 Bernstein D (2018) Cardiovascular Receptors and Signaling in Heart Failure Heart Failure in the Child and Young Adult, 10.1016/B978-0-12-802393-8.00002-8, (21-31), . Spadari R, Cavadas C, de Carvalho A, Ortolani D, de Moura A and Vassalo P (2017) Role of Beta-adrenergic Receptors and Sirtuin Signaling in the Heart During Aging, Heart Failure, and Adaptation to Stress, Cellular and Molecular Neurobiology, 10.1007/s10571-017-0557-2, 38:1, (109-120), Online publication date: 1-Jan-2018. Nakib I, Martin-Eauclaire M and Laraba-Djebari F (2016) Involvement of Cholinergic and Adrenergic Receptors in Pathogenesis and Inflammatory Response Induced by Alpha-Neurotoxin Bot III of Scorpion Venom, Inflammation, 10.1007/s10753-016-0401-8, 39:5, (1670-1680), Online publication date: 1-Oct-2016. Woo A, Song Y, Xiao R and Zhu W (2014) Biased β 2 -adrenoceptor signalling in heart failure: pathophysiology and drug discovery , British Journal of Pharmacology, 10.1111/bph.12965, 172:23, (5444-5456), Online publication date: 1-Dec-2015. Montó F, Oliver E, Vicente D, Buendía F, Rueda J, Agüero J, Almenar L, Valldecabres C, Rovira E, Muedra V, Noguera M, Ivorra M and DʼOcon P (2015) β2- and β1-Adrenoceptor Expression Exhibits a Common Regulatory Pattern With GRK2 and GRK5 in Human and Animal Models of Cardiovascular Diseases, Journal of Cardiovascular Pharmacology, 10.1097/FJC.0000000000000299, 66:5, (478-486), Online publication date: 1-Nov-2015. Odnoshivkina U, Sytchev V, Nurullin L, Giniatullin A, Zefirov A and Petrov A (2015) β2-adrenoceptor agonist-evoked reactive oxygen species generation in mouse atria: implication in delayed inotropic effect, European Journal of Pharmacology, 10.1016/j.ejphar.2015.08.020, 765, (140-153), Online publication date: 1-Oct-2015. Hattori Y, Hattori K and Suzuki T (2015) Differential Modulation of Cardiac Sympathetic Neural Control and β-Adrenoceptor–G Protein Signaling Cascade in Rats With Type 1 and Type 2 Diabetes, Diabetes, 10.2337/db15-0503, 64:8, (2708-2710), Online publication date: 1-Aug-2015. Soriano-Ursúa M, Trujillo-Ferrara J, Arias-Montaño J and Villalobos-Molina R (2015) Insights into a defined secondary binding region on β-adrenoceptors and putative roles in ligand binding and drug design, MedChemComm, 10.1039/C5MD00011D, 6:6, (991-1002) Lu C, Sun Z and Wang L (2015) Inhibition of L-type Ca2+ current by ginsenoside Rd in rat ventricular myocytes, Journal of Ginseng Research, 10.1016/j.jgr.2014.11.003, 39:2, (169-177), Online publication date: 1-Apr-2015. Nyman E, Lindgren I, Lövfors W, Lundengård K, Cervin I, Sjöström T, Altimiras J and Cedersund G (2015) Mathematical modeling improves EC 50 estimations from classical dose-response curves , FEBS Journal, 10.1111/febs.13194, 282:5, (951-962), Online publication date: 1-Mar-2015. Reinartz M, Kälble S, Littmann T, Ozawa T, Dove S, Kaever V, Wainer I and Seifert R (2014) Structure-bias relationships for fenoterol stereoisomers in six molecular and cellular assays at the β2-adrenoceptor, Naunyn-Schmiedeberg's Archives of Pharmacology, 10.1007/s00210-014-1054-5, 388:1, (51-65), Online publication date: 1-Jan-2015. Melsom C, Hussain R, Ørstavik Ø, Aronsen J, Sjaastad I, Skomedal T, Osnes J, Levy F and Krobert K (2014) Non-classical regulation of β1- and β2-adrenoceptor-mediated inotropic responses in rat heart ventricle by the G protein Gi, Naunyn-Schmiedeberg's Archives of Pharmacology, 10.1007/s00210-014-1036-7, 387:12, (1177-1186), Online publication date: 1-Dec-2014. Yang J, Liu Y, Fan X, Li Z and Cheng Y (2013) A pathway and network review on beta-adrenoceptor signaling and beta blockers in cardiac remodeling, Heart Failure Reviews, 10.1007/s10741-013-9417-4, 19:6, (799-814), Online publication date: 1-Nov-2014. Bosier B and Hermans E (2014) Promises of Biased Signaling in the Development of Improved Therapeutics Biased Signaling in Physiology, Pharmacology and Therapeutics, 10.1016/B978-0-12-411460-9.00008-2, (251-292), . Salazar N, Vallejos X, Siryk A, Rengo G, Cannavo A, Liccardo D, De Lucia C, Gao E, Leosco D, Koch W and Lymperopoulos A (2013) GRK2 blockade with βARKct is essential for cardiac β2-adrenergic receptor signaling towards increased contractility, Cell Communication and Signaling, 10.1186/1478-811X-11-64, 11:1, Online publication date: 1-Dec-2013. Soriano-Ursúa M, Trujillo-Ferrara J, Correa-Basurto J and Vilar S (2013) Recent Structural Advances of β1 and β2 Adrenoceptors Yield Keys for Ligand Recognition and Drug Design, Journal of Medicinal Chemistry, 10.1021/jm400471z, 56:21, (8207-8223), Online publication date: 14-Nov-2013. Fajardo G, Zhao M, Urashima T, Farahani S, Hu D, Reddy S and Bernstein D (2013) Deletion of the β2-adrenergic receptor prevents the development of cardiomyopathy in mice, Journal of Molecular and Cellular Cardiology, 10.1016/j.yjmcc.2013.07.016, 63, (155-164), Online publication date: 1-Oct-2013. Pérez-Schindler J, Philp A and Hernandez-Cascales J (2013) Pathophysiological relevance of the cardiac β2-adrenergic receptor and its potential as a therapeutic target to improve cardiac function, European Journal of Pharmacology, 10.1016/j.ejphar.2012.11.001, 698:1-3, (39-47), Online publication date: 1-Jan-2013. van Deursen C, van Middendorp L and Prinzen F (2013) Dyssynchronous Heart Failure: From Bench to Bedside Translational Approach to Heart Failure, 10.1007/978-1-4614-7

Abstract:HomeCirculation ResearchVol. 87, No. 8Cell Logic for Dual Coupling of a Single Class of Receptors to Gs and Gi Proteins Free AccessEditorialPDF/EPUBAboutView PDFView EPUBSections ToolsAdd to favoritesDownload citationsTrack citationsPermissions ShareShare onFacebookTwitterLinked InMendeleyReddit Jump toFree AccessEditorialPDF/EPUBCell Logic for Dual Coupling of a Single Class of Receptors to Gs and Gi Proteins Rui-Ping Xiao Rui-Ping XiaoRui-Ping Xiao From the Laboratory of Cardiovascular Science, Gerontology Research Center, National Institute on Aging, National Institutes of Health, Baltimore, Md. Search for more papers by this author Originally published13 Oct 2000https://doi.org/10.1161/01.RES.87.8.635Circulation Research. 2000;87:635–637Gprotein–coupled receptors mediate transmembrane signal transduction for a variety of hormones, neurotransmitters, chemokines, and synthetic ligands. It had been thought that a given receptor couples only to a single class of heterotrimeric G proteins to achieve signaling selectivity and specificity. As a model system of G protein–coupled receptors, β-adrenergic receptor (βAR) was believed to activate exclusively a Gs-adenylyl cyclase-cAMP-protein kinase A (PKA) signaling cascade. This doctrine, however, has been challenged by recent findings that, although seeming illogical, β2AR dually couples to Gs and Gi proteins in rodent and canine hearts123 (for review, see Reference 4 ). In this issue of Circulation Research, Kilts et al5 present a solid study that provides additional evidence supporting a dual G protein coupling for β2AR and extended the previous finding to several other Gs-coupled receptors in human heart.Gs and Gi DichotomyEarly studies showed that stimulation of β1AR, but not β2AR, induces a relaxant effect,67 a hallmark of cAMP-dependent cardiac modulation. Moreover, β2AR-induced augmentations in intracellular Ca2+ transient and contractility are apparently dissociated from cellular cAMP accumulation and PKA-mediated protein phosphorylation in rat ventricular myocytes, whereas the classic linear Gs-adenylyl cyclase-cAMP-PKA signaling cascade is corroborated for β1AR stimulation.8 These findings provided the first clue that there are some substantial differences between β1AR and β2AR signaling pathways.In search for answers to the anomalous behavior of cardiac β2AR stimulation, recent studies have revealed dichotomous G protein coupling for native β2AR under physiological conditions. Disrupting Gi signaling by pertussis toxin (PTX)–mediated ribosylation enhances β2AR-induced contractile response in rat ventricular myocytes1 and unmasks the β2AR positive inotropic effect in mouse cardiac myocytes, in which Gi signaling fully negates β2AR/Gs-mediated contractile response.2 More recently, photoaffinity labeling of G proteins with [32P]-azidoanilido-GTP in conjunction with immunoprecipitation with antibodies specific for Gαs and Gαi provided direct biochemical evidence that β2AR activates both Gs and Gi (Gαi2 and Gαi3) signaling pathways, whereas β1AR selectively activates Gs in adult mouse cardiac myocytes.2 By photolabeling human atrial membranes with [32P]-azidoanilido-GTP, Kilts et al5 further demonstrated that cardiac Gαi is activated by stimulation of β2AR and several other Gαs-coupled receptors, including histamine, serotonin, and glucagon receptors. Thus, promiscuous G protein coupling seems to be a rather common pattern of receptor–G protein interaction in the physiological context, although this property is not shared by β1AR. These findings raise important questions regarding physiological and pathophysiological relevance of the additional Gi coupling of Gs-coupled receptors.Cell Logic for Receptor Coupling to More Than One G ProteinTransmembrane receptor signaling is a complex biological process orchestrated by a myriad of receptors and G proteins. The interplay of Gs and Gi signaling has been clearly elucidated in crosstalk between different receptor families. For example, stimulation of Gi-coupled muscarinic receptors attenuates the positive inotropic effect of βAR stimulation.910 However, cardiac β2AR and several other Gs-coupled receptors present intriguing cases in which crosstalk occurs between concurrent Gs and Gi signaling pathways originating from a single class of receptors. We are only beginning to appreciate the cellular logic behind the “one receptor, two G protein” signaling mechanism.Although Gi is named for its inhibitory effect on adenylyl cyclase and activation of Gi may counteract the ability of Gs to stimulate adenylyl cyclase, as demonstrated by Kilts et al,5 it is noteworthy that the Gs and Gi interaction is not necessarily confined to the cyclase level.311 Counterintuitively, promiscuous G protein coupling may enhance, rather than compromise, the receptor signaling specificity. This point is perhaps best exemplified by βAR subtype stimulation. In rodent and canine hearts, β1AR stimulation increases phosphorylation of phospholamban, which accelerates Ca2+ sequestration into the sarcoplasmic reticulum, resulting in accelerated cardiac relaxation,46812 and increases phosphorylation of troponin I and C protein,12 which reduces myofilament sensitivity to Ca2+. In contrast, β2AR stimulation modulates specifically L-type Ca2+ channels, bypassing the aforementioned intracellular regulatory proteins.36812 In a direct approach involving on-cell patch-clamp recordings, it has been shown that β2AR stimulation modulates single L-type Ca2+ channel activity only in a local mode (agonist included in pipette solution) but not in a remote mode (agonist added to bathing solution outside the patch), whereas β1AR stimulation does so in either mode.13 Gi activation is essential to the spatial localization and effector selectivity of β2 AR signaling, because inhibiting Gi function with PTX permits a remote β2AR effect on L-type Ca2+ channels13 and a robust increase in phospholamban phosphorylation as well as a markedly accelerated relaxation in response to β2AR stimulation.3Equally appealing, Gi activation may deliver Gs-independent signals through Giα and Giβγ, further enriching receptor signaling diversity. For example, stimulation of the recombinant β2AR transiently expressed in HEK 293 cells activates both Gs and Gi; the latter increases the activity of mitogen-activated protein kinase,14 which plays an important role in regulating chronic cellular processes such as cell growth and cell death.In principle, the aforementioned interplay between Gs and Gi signals could be conducted by two types of receptors coupled to Gs and Gi, respectively. In contrast to the “two receptor, two G protein” system, the beauty of the “one receptor, two G protein” design is that it ensures a proportional activation of the dual G protein signals and affords a spatial and temporal colocalization and coordination of these signals. The delicate balance of Gs and Gi signaling in space and time might be crucial to normal cellular functions.Pathophysiological RelevanceProgrammed cell death or apoptosis has been recently implicated as a consequence of cardiac ischemic/reperfusion injury, contributing to the transition from cardiac hypertrophy to decompensatory heart failure.151617 In vivo and in vitro studies indicate that β1AR and β2AR exhibit distinctly different, even opposing, effects on cardiac myocyte apoptosis. In cultured adult rat cardiac myocytes, stimulation of β1AR, but not β2AR, induces myocyte apoptosis.18 Using a β1β2AR double knockout mouse model in conjunction with adenoviral gene transfer, we have created pure βAR subtype experimental settings and found that β1AR stimulation markedly induces myocyte apoptosis. In contrast, β2AR stimulation activates concurrent apoptotic and survival signals mediated by Gi and Gs, respectively, with the Gi-mediated survival effect predominant (Zhu W-Z, Zheng M, Kolbilka BK, Xiao R-P, unpublished data, 2000). Moreover, activation of β2AR-coupled Gi protects cardiac myocytes from a range of apoptotic assaults, including hypoxia or reactive oxygen species–induced apoptosis (Chesley A, Ohtani S, Asai T, Xiao R-P, Lunberg MS, Lakatta EG, Crow MT, unpublished data, 2000).Chronic stimulation of these βAR subtypes in the heart also elicits strikingly different phenotypes in murine transgenic models. Overexpression of cardiac β1AR by ≈5- to 46-fold induces cardiac hypertrophy, apoptosis, and fibrosis within a few weeks after birth and heart failure within several months.1920 Ironically, overexpression of cardiac β2AR by ≈100- to 200-fold does not induce hypertrophy or heart failure,212223 at least up to the age of 1 year. However, overwhelming expression of β2AR (eg, ≈350- to 1000-fold) induces pathological phenotypes,2223 perhaps caused by a mechanic and metabolic overload (markedly enhanced baseline adenylyl cyclase activity and cardiac contractility) due to spontaneous β2AR activation. Whether the distinct phenotypes of β2AR versus β1AR mouse transgenic models are related to their different G protein coupling merits further investigations.Although activation of β2AR-coupled Gi protects cardiac myocytes against apoptosis, an imbalance of β2AR-initiated Gs and Gi signaling pathways may induce pathological consequences. Chronic heart failure in human and animal models is characterized by a diminished contractile response to βAR stimulation,242526272829 accompanied by a selective downregulation of β1AR (higher β2/β1 ratio)24252627 and an increase in the amount or activity of Gi proteins.2728293031 In light of the Gs and Gi dichotomy, the upregulation of Gi may participate in the defect of βAR inotropic effect in the decompensated failing heart. This idea is supported by recent observations that PTX treatment restores the diminished βAR inotropic response in a rat myocardial infarction heart failure model32 and in myocytes from failing human hearts.33On the basis of these findings, we speculate that the selective downregulation of β1AR and the upregulation of β2AR/Gi signaling in functionally compensated hypertrophic heart or early stage of heart failure may represent a cardiac protective mechanism (eg, against myocyte apoptosis), which slows the progression of cardiomyopathy and contractile dysfunction. However, exaggerated β2AR/Gi signaling may blunt Gs-mediated contractile support, contributing to the phenotype of decompensated heart failure.Therapeutic ImplicationsIt has been highly controversial as to whether enhancing βAR signaling is beneficial or deleterious for the failing heart. The prevalent view is that chronically increasing nonselective βAR stimulation is toxic to the heart, because there is an inverse relationship between the plasma level of norepinephrine and the survival of patients with heart failure34 and because βAR blockade (eg, by β1AR antagonists bisoprolol and metoprolol or a nonselective βAR blocker carvedilol) reduces both the morbidity and mortality in patients with heart failure.35 However, the discovery of a new paradigm of β2AR signaling (ie, the dual G protein coupling), the opposing effects of stimulation of these βAR subtypes on cardiomyocyte apoptosis, and the distinct phenotypes of cardiac-specific overexpression of β1AR versus β2AR underscore the necessity and importance of distinguishing β2AR signaling from that of β1AR in terms of their cardiac functional roles and therapeutic implications.In our opinion, selectively enhancing β2AR signaling may provide a novel therapeutic strategy in the prevention and treatment of chronic heart failure. Indeed, crossing transgenic mice overexpressing cardiac β2AR at appropriate levels (eg, 30-fold) with transgenic mice overexpressing Gqα not only improves the cardiac performance but also reverses hypertrophy in the Gqα overexpression heart failure model,22 although extremely high levels of β2AR overexpression (eg, ≈350- to 1000-fold) fail to rescue the genetic mouse heart failure model.22 Additionally, the beneficial effect of β2AR stimulation in the context of heart failure is clearly supported by the analysis of polymorphisms of β2AR in chronic heart failure patients. The likelihood of earlier aggressive intervention or cardiac transplantation is significantly greater in heart failure patients with Ile164 polymorphism (a Thr to Ile switch at amino acid 164 with reduced β2AR signaling efficacy) relative to patients without the β2AR variant.36In summary, coupling of one receptor to more than one class of G proteins may represent a common property of many Gs-coupled receptors, rather than a unique quality of β2AR. The additional Gi coupling not only confers spatial and temporal control of Gs-stimulated signals, enhancing the receptor signaling specificity, but also enriches signaling diversity by delivering Gs-independent signals. The discovery of the Gs and Gi dichotomy reshapes our current understanding of receptor–G protein interactions in physiological systems. An imbalance of the concurrent Gs and Gi signals may have important pathophysiological relevance and clinic implications.The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.I would like to thank Drs Edward G. Lakatta and Heping Cheng for critical discussions and comments.FootnotesCorrespondence to Rui-Ping Xiao, MD, PhD, Laboratory of Cardiovascular Science, Gerontology Research Center, NIA, NIH, 5600 Nathan Shock Dr, Baltimore, MD 21224. E-mail [email protected] References 1 Xiao RP, Ji X, Lakatta EG. Functional coupling of the β2-adrenoceptor to a pertussis toxin-sensitive G protein in cardiac myocytes. Mol Pharmacol.1995; 47:322–329.MedlineGoogle Scholar2 Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA, Eschenhagen T, Lefkowitz RJ, Koch WJ, Lakatta EG. Coupling of β2-adrenoceptor to Gi proteins and its physiological relevance in murine cardiac myocytes. Circ Res.1999; 84:43–52.CrossrefMedlineGoogle Scholar3 Kuschel M, Zhou Y-Y, Cheng H, Zhang SJ, Chen Y, Lakatta EG, Xiao R-P. Gi protein-mediated functional compartmentalization of cardiac β2-adrenergic signaling. J Biol Chem.1999; 274:22048–22052.CrossrefMedlineGoogle Scholar4 Xiao R-P, Cheng H, Zhou Y-Y, Kuschel M, Lakatta EG. Recent advances in cardiac β-adrenergic receptor subtype signal transduction. Circ Res.1999; 85:1092–1100.CrossrefMedlineGoogle Scholar5 Kilts JD, Gerhardt MA, Richardson MD, Sreeram G, Mackensen GB, Grocott HP, White WD, Davis RD, Newman MF, Reves JG, Schwinn DA, Kwatra MM. β2-Adrenergic and several other G protein–coupled receptors in human atrial membranes activate both Gs and Gi. Circ Res.2000; 87:705–709.CrossrefMedlineGoogle Scholar6 Xiao RP, Lakatta EG. β1-Adrenoceptor stimulation and β2-adrenoceptor stimulation differ in their effects on contraction, cytosolic Ca2+, and Ca2+ current in single rat ventricular cells. Circ Res.1993; 73:286–300.CrossrefMedlineGoogle Scholar7 Kuznetsov V, Pak E, Robinson RB, Steinberg SF. β2-Adrenergic receptor actions in neonatal and adult rat ventricular myocytes. Circ Res.1995; 76:40–52.CrossrefMedlineGoogle Scholar8 Xiao RP, Hohl C, Altschuld R, Jones L, Livingston B, Ziman B, Tantini B, Lakatta EG. β2-Adrenergic receptor-stimulated increase in cAMP in rat heart cells is not coupled to changes in Ca2+ dynamics, contractility, or phospholamban phosphorylation. J Biol Chem.1994; 269:19151–19156.CrossrefMedlineGoogle Scholar9 Levy MN, Martin PJ, Stuesse SL. Neural regulation of the heart beat. Annu Rev Physiol.1981; 43:443–453.CrossrefMedlineGoogle Scholar10 Gupta RC, Neumann J, Boknik P, Watanabe AM. M2-specific muscarinic cholinergic receptor-mediated inhibition of cardiac regulatory protein phosphorylation. Am J Physiol.1994; 266:H1138–H1144.MedlineGoogle Scholar11 Zhou YY, Cheng H, Bogdanov KY, Hohl C, Altschuld R, Lakatta EG, Xiao RP. Localized cAMP-dependent signaling mediates β2-adrenergic modulation of cardiac excitation-contraction coupling. Am J Physiol.1997; 273:H1611–H1618.CrossrefMedlineGoogle Scholar12 Kuschel M, Zhou Y-Y, Spurgeon HA, Bartel S, Karczewski P, Zhang SJ, Krause E-G, Lakatta EG, Xiao R-P. β2-Adrenergic cAMP signaling is uncoupled from phosphorylation of cytoplasmic proteins in canine heart. Circulation.1999; 99:2458–2465.CrossrefMedlineGoogle Scholar13 Chen Y, Xiao R-P, Izu LT, Cheng H, Kuschel M, Spurgeon H, Lakatta EG. Gi-dependent localization of β2-adrenergic receptor signaling to L-type Ca2+ channels. Biophys J. In press.Google Scholar14 Daaka Y, Luttrell LM, Lefkowitz RJ. Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A. Nature.1997; 390:88–91.CrossrefMedlineGoogle Scholar15 Teiger E, Than VD, Richard L, Wisnewsky C, Tea BS, Gaboury L, Tremblay J, Schwartz K, Hamet P. Apoptosis in pressure overload-induced heart hypertrophy in the rat. J Clin Invest.1996; 97:2891–2897.CrossrefMedlineGoogle Scholar16 Adams JW, Sakata Y, Davis MG, Sah VP, Wang Y, Liggett SB, Chien KR, Brown JH, Dorn GW II. Enhanced Gαq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure. Proc Natl Acad Sci U S A.1998; 95:10140–10145.CrossrefMedlineGoogle Scholar17 Olivetti G, Abbi R, Quaini F, Kajstura J, Cheng W, Nitahara JA, Quaini E, Di Loreto C, Beltrami CA, Krajewski S, Reed JC, Anversa P. Apoptosis in the failing humans heart. N Engl J Med.1997; 336:1131–1141.CrossrefMedlineGoogle Scholar18 Communal C, Singh K, Sawyer DB, Colucci WS. Opposing effects of β1- and β2-adrenergic receptors on cardiac myocyte apoptosis: role of a pertussis toxin-sensitive G protein. Circulation.1999; 100:2210–2212.CrossrefMedlineGoogle Scholar19 Engelhardt S, Hein L, Wiesmann F, Lohse MJ. Progressive hypertrophy and heart failure in β1-adrenergic receptor transgenic mice. Proc Natl Acad Sci U S A.1999; 96:7059–7064.CrossrefMedlineGoogle Scholar20 Bisognano JD, Weinberger HD, Bohlmeyer TJ, Pende A, Raynolds MV, Sastravaha A, Roden R, Asano K, Blaxall BC, Wu SC, Communal C, Singh K, Colucci W, Bristow MR, Port DJ. Myocardial-directed overexpression of the human β1-adrenergic receptor in transgenic mice. J Mol Cell Cardiol.2000; 32:817–830.CrossrefMedlineGoogle Scholar21 Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR, Chien KR, Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial function in transgenic mice overexpressing the β2-adrenergic receptor. Science.1994; 264:582–586.CrossrefMedlineGoogle Scholar22 Dorn GW II, Tepe NM, Lorenz JN, Koch WJ, Liggett SB. Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice. Proc Natl Acad Sci U S A.1999; 96:6400–6405.CrossrefMedlineGoogle Scholar23 Liggett SB, Tepe NM, Lorenz JN, Canning AM, Jantz TD, Mitarai S, Yatani A, Dorn GW II. Early and delayed consequences of β2-adrenergic receptor overexpression in mouse hearts: critical role for expression level. Circulation.2000; 101:1707–1714.CrossrefMedlineGoogle Scholar24 Bristow MR, Ginsburg R, Minobe W, Cubicciotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB. Decreased catecholamine sensitivity and β-adrenergic-receptor density in failing human hearts. N Engl J Med.1982; 307:205–211.CrossrefMedlineGoogle Scholar25 Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W, Rasmussen R, Zera P, Menlove R, Shah P, Jamieson SEB. β1- and β2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective β1-receptor down-regulation in heart failure. Circ Res.1986; 59:297–309.LinkGoogle Scholar26 Brodde OE. β1- and β2-Adrenoceptors in the human heart: properties, function, and alterations in chronic heart failure. Pharmacol Rev.1991; 43:203–242.MedlineGoogle Scholar27 Kiuchi K, Shannon RP, Komamura K, Cohen DJ, Bianchi C, Homcy CJ, Vatner SF, Vatner DE. Myocardial β-adrenergic receptor function during the development of pacing-induced heart failure. J Clin Invest.1993; 91:907–914.CrossrefMedlineGoogle Scholar28 Gu XH, Kompa AR, Summers RJ. Regulation of β-adrenoceptors in a rat model of cardiac failure: effect of perindopril. J Cardiovasc Pharmacol.1998; 32:66–74.CrossrefMedlineGoogle Scholar29 Hammond HK. Mechanisms for myocardial β-adrenergic receptor desensitization in heart failure. Circulation.1993; 87:652–654.CrossrefMedlineGoogle Scholar30 Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A, Hirt S, Doring V, Kalmar P, Hoppner W. Increased messenger RNA level of the inhibitory G protein α subunit Giα2 in human end-stage heart failure. Circ Res.1992; 70:688–696.CrossrefMedlineGoogle Scholar31 Bohm M, Eschenhagen T, Gierschik P, Larisch K, Lensche H, Mende U, Schmitz W, Schnabel P, Scholz H, Steinfath M. Radioimmunochemical quantification of Giα in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Cell Cardiol.1994; 26:133–149.CrossrefMedlineGoogle Scholar32 Kompa AR, Gu XH, Evans BA, Summers RJ. Desensitization of cardiac β-adrenoceptor signaling with heart failure produced by myocardial infarction in the rat: evidence for the role of Gi but not Gs or phosphorylating proteins. J Mol Cell Cardiol.1999; 31:1185–1201.CrossrefMedlineGoogle Scholar33 Brown LA, Harding SE. The effect of pertussis toxin on β-adrenoceptor responses in isolated cardiac myocytes from noradrenaline-treated guinea-pigs and patients with cardiac failure. Br J Pharmacol.1992; 106:115–122.CrossrefMedlineGoogle Scholar34 Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med.1984; 311:819–823.CrossrefMedlineGoogle Scholar35 Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation.1996; 94:2285–2296.CrossrefMedlineGoogle Scholar36 Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, McIntosh TC, Walsh RA. The Ile164 β2-adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest.1998; 102:1534–1539.CrossrefMedlineGoogle Scholar Previous Back to top Next FiguresReferencesRelatedDetailsCited By Liu Z, Tao B, Fan S, Cui S, Pu Y, Qiu L, Xia H and Xu L (2020) Over-expression of microRNA-145 drives alterations in β-adrenergic signaling and attenuates cardiac remodeling in heart failure post myocardial infarction, Aging, 10.18632/aging.103320, 12:12, (11603-11622), Online publication date: 18-Jun-2020. Gao Z, Inoue A and Jacobson K (2018) On the G protein-coupling selectivity of the native A2B adenosine receptor, Biochemical Pharmacology, 10.1016/j.bcp.2017.12.003, 151, (201-213), Online publication date: 1-May-2018. Hutter D (2018) The Human Embryo and Its Environment: In Utero Challenges and Physiological Outcomes Development and Environment, 10.1007/978-3-319-75935-7_16, (403-420), . Hutter D, Kingdom J and Jaeggi E (2010) Causes and Mechanisms of Intrauterine Hypoxia and Its Impact on the Fetal Cardiovascular System: A Review, International Journal of Pediatrics, 10.1155/2010/401323, 2010, (1-9), . Xu L, Lai D, Cheng J, Lim H, Keskanokwong T, Backs J, Olson E and Wang Y (2010) Alterations of L-Type Calcium Current and Cardiac Function in CaMKIIδ Knockout Mice, Circulation Research, 107:3, (398-407), Online publication date: 6-Aug-2010. Ryall J and Lynch G (2008) The potential and the pitfalls of β-adrenoceptor agonists for the management of skeletal muscle wasting, Pharmacology & Therapeutics, 10.1016/j.pharmthera.2008.06.003, 120:3, (219-232), Online publication date: 1-Dec-2008. Wu Q, Zhao Z, Sun H, Hao Y, Yan C and Gu S (2008) Oestrogen changed cardiomyocyte contraction and β-adrenoceptor expression in rat hearts subjected to ischaemia-reperfusion, Experimental Physiology, 10.1113/expphysiol.2007.041939, 93:9, (1034-1043), Online publication date: 1-Sep-2008. Bruss M, Richter W, Horner K, Jin S and Conti M (2008) Critical Role of PDE4D in β2-Adrenoceptor-dependent cAMP Signaling in Mouse Embryonic Fibroblasts, Journal of Biological Chemistry, 10.1074/jbc.M803306200, 283:33, (22430-22442), Online publication date: 1-Aug-2008. Penner R and Fleig A The Mg2+ and Mg2+-Nucleotide-Regulated Channel-Kinase TRPM7 Transient Receptor Potential (TRP) Channels, 10.1007/978-3-540-34891-7_19, (313-328) Vandeput F, Wolda S, Krall J, Hambleton R, Uher L, McCaw K, Radwanski P, Florio V and Movsesian M (2007) Cyclic Nucleotide Phosphodiesterase PDE1C1 in Human Cardiac Myocytes, Journal of Biological Chemistry, 10.1074/jbc.M703173200, 282:45, (32749-32757), Online publication date: 1-Nov-2007. Brum P, Rolim N, Bacurau A and Medeiros A (2006) Neurohumoral activation in heart failure: the role of adrenergic receptors, Anais da Academia Brasileira de Ciências, 10.1590/S0001-37652006000300009, 78:3, (485-503), Online publication date: 1-Sep-2006. Xu K, Takimoto E and Fedarko N (2006) Activation of (Na++K+)-ATPase induces positive inotropy in intact mouse heart in vivo, Biochemical and Biophysical Research Communications, 10.1016/j.bbrc.2006.08.070, 349:2, (582-587), Online publication date: 1-Oct-2006. Wroblewska B, Wegorzewska I, Bzdega T, Olszewski R and Neale J (2006) Differential negative coupling of type 3 metabotropic glutamate receptor to cyclic GMP levels in neurons and astrocytes, Journal of Neurochemistry, 10.1111/j.1471-4159.2005.03569.x, 96:4, (1071-1077), Online publication date: 1-Feb-2006. Santos I, Sumitame M, Caceres V, Moreira M, Krieger M and Spadari-Bratfisch R (2005) Evidence for two atypical conformations of beta-adrenoceptors and their interaction with Gi proteins, European Journal of Pharmacology, 10.1016/j.ejphar.2005.03.008, 513:1-2, (109-118), Online publication date: 1-Apr-2005. Zhang L (2016) Prenatal Hypoxia and Cardiac Programming, Journal of the Society for Gynecologic Investigation, 10.1016/j.jsgi.2004.09.004, 12:1, (2-13), Online publication date: 1-Jan-2005. Tong H, Bernstein D, Murphy E and Steenbergen C (2005) The role of β‐Adrenergic Receptor Signaling in Cardioprotection, The FASEB Journal, 10.1096/fj.04-3067fje, 19:8, (983-985), Online publication date: 1-Jun-2005. Heubach J, Ravens U and Kaumann A (2004) Epinephrine Activates Both G s and G i Pathways, but Norepinephrine Activates Only the G s Pathway through Human β 2 -Adrenoceptors Overexpressed in Mouse Heart , Molecular Pharmacology, 10.1124/mol.65.5.1313, 65:5, (1313-1322), Online publication date: 1-May-2004. Liang W, Curran P, Hoang Q, Moreland R and Fishman P (2004) Differences in endosomal targeting of human β1- and β2-adrenergic receptors following clathrin-mediated endocytosis, Journal of Cell Science, 10.1242/jcs.00878, 117:5, (723-734), Online publication date: 15-Feb-2004. Hasseldine A, Harper E and Black J (2009) Cardiac-specific overexpression of human β 2 adrenoceptors in mice exposes coupling to both G s and G i proteins , British Journal of Pharmacology, 10.1038/sj.bjp.0705191, 138:7, (1358-1366), Online publication date: 1-Apr-2003. Bae S, Xiao Y, Li G, Casiano C and Zhang L (2003) Effect of maternal chronic hypoxic exposure during gestation on apoptosis in fetal rat heart, American Journal of Physiology-Heart and Circulatory Physiology, 10.1152/ajpheart.00005.2003, 285:3, (H983-H990), Online publication date: 1-Sep-2003. Tse R, Marroquin B, Dorscheid D and White S (2003) β-Adrenergic agonists inhibit corticosteroid-induced apoptosis of airway epithelial cells, American Journal of Physiology-Lung Cellular and Molecular Physiology, 10.1152/ajplung.00030.2003, 285:2, (L393-L404), Online publication date: 1-Aug-2003. Xiang Y and Kobilka B (2003) The PDZ-binding motif of the β 2 -adrenoceptor is essential for physiologic signaling and trafficking in cardiac myocytes , Proceedings of the National Academy of Sciences, 10.1073/pnas.1831718100, 100:19, (10776-10781), Online publication date: 16-Sep-2003. Li G, Xiao Y, Estrella J, Ducsay C, Gilbert R and Zhang L (2016) Effect of Fetal Hypoxia on Heart Susceptibility to Ischemia and Reperfusion Injury in the Adult Rat, Journal of the Society for Gynecologic Investigation, 10.1016/S1071-55760300074-1, 10:5, (265-274), Online publication date: 1-Jul-2003. Liang W, Austin S, Hoang Q and Fishman P (2003) Resistance of the Human β1-Adrenergic Receptor to Agonist-mediated Down-regulation, Journal of Biological Chemistry, 10.1074/jbc.M304482200, 278:41, (39773-39781), Online publication date: 1-Oct-2003. Xiang Y and Kobilka B (2003) Myocyte Adrenoceptor Signaling Pathways, Science, 10.1126/science.1079206, 300:5625, (1530-1532), Online publication date: 6-Jun-2003. Tuček S, Michal P and Vlachová V (2002) Modelling the consequences of receptor–G-protein promiscuity, Trends in Pharmacological Sciences, 10.1016/S0165-6147(00)01996-9, 23:4, (171-176), Online publication date: 1-Apr-2002. See Hoe L, Bartnikowski N, Wells M, Suen J and Fraser J (2019) Hurdles to Cardioprotection in the Critically Ill, International Journal of Molecular Sciences, 10.3390/ijms20153823, 20:15, (3823) October 13, 2000Vol 87, Issue 8 Advertisement Article InformationMetrics © 2000 American Heart Association, Inc.https://doi.org/10.1161/01.RES.87.8.635 Originally publishedOctober 13, 2000 Keywordsβ-adrenergic receptor subtypescAMP compartmentalizationdual G protein couplingheart failurePDF download Advertisement

The Enigma Of Beta(2)-Adrenergic Receptor G(I) Signaling In The Heart - The Good, The Bad, And The Ugly

The Enigma of Β 2 -Adrenergic Receptor G I Signaling in the Heart

Β-Adrenergic Signaling in the Heart: Dual Coupling of the Β2-Adrenergic Receptor to Gs and Gi Proteins

Distinct Beta-Adrenergic Receptor Subtype Signaling in the Heart and Their Pathophysiological Relevance.

Na+/Ca2+ exchange linking beta2-adrenergic G(i) signaling to heart failure: associated defect of adrenergic contractile support.

Emerging Concepts and Therapeutic Implications of Β-Adrenergic Receptor Subtype Signaling

Enhanced G(I) Signaling Selectively Negates Beta(2)-Adrenergic Receptor (Ar)- But Not Beta(1)-Ar-Mediated Positive Inotropic Effect In Myocytes From Failing Rat Hearts

Cardiac β-Adrenoceptor Signaling: The New Insight on An Old Target in the Therapy of Cardiovascular Disease

Recent Advances in Cardiac Β 2 -Adrenergic Signal Transduction

Coupling of Beta(2)-Adrenoceptor to G(I) Proteins and Its Physiological Relevance in Murine Cardiac Myocytes

Stimulation of Β-Adrenoceptor Subtypes Causes Different Effects in Cardiac Cells

Internalized β2-Adrenergic Receptors Oppose PLC-Dependent Hypertrophic Signaling

Protecting The Myocardium: A Role For The Beta 2 Adrenergic Receptor In The Heart

Effect in Myocytes From Failing Rat Hearts

Heterologous Desensitization of Cardiac Β-Adrenergic Signal Via Hormone-Induced Βar/arrestin/pde4 Complexes.

Cell Logic for Dual Coupling of a Single Class of Receptors to G(s) and G(i) Proteins.

Beta(2)-Adrenergic Camp Signaling Is Uncoupled From Phosphorylation Of Cytoplasmic Proteins In Canine Heart

Subtype-specific Beta-Adrenoceptor Signaling Pathways in the Heart and Their Potential Clinical Implications.

Constitutive Beta(2)-Adrenergic Signalling Enhances Sarcoplasmic Reticulum Ca2+ Cycling to Augment Contraction in Mouse Heart

Beta-adrenoceptor Signaling Pathways Mediate Cardiac Pathological Remodeling.

Inhibition of Spontaneous Β2-Adrenergic Activation Rescues Β1-Adrenergic Contractile Response in Cardiomyocytes Overexpressing Β2-Adrenoceptor